Table 2.
Molecular Abnormalities in Thymic Malignancies
| Oncogene/Molecular Change | Thymoma (%) | Thymic Carcinoma (%) | Reference |
|---|---|---|---|
| EGFR | |||
| Gene amplification (FISH) | 20 | 25 | Lonescu et al18 |
| Overexpression (IHC) | 23 | 67-100 | Suzuki et al,19 Henley et al,20 Hayashi et al21 |
| HER2 | |||
| Overexpression (IHC) | 6 | 53 | Pan et al22 |
| c-KIT (CD117) | |||
| Overexpression (IHC) | < 5 | 73-86 | Nakagawa et al,23 Pan et al24 |
| BCL2 | |||
| Overexpression (IHC) | 14 | 100 | Pan et al22 |
| Tumor suppressor genes | |||
| TP53 | |||
| LOH | 0 | 38 | Penzel et al25 |
| Mutation | 0 | 11-30 | Tateyama et al,26 Chen et al,27 Pich et al,28 Weirich et al29 |
| Overexpression (IHC) | 12-100 | 80-100 | Tateyama et al,26 Weirich et al,29 Hirabyashi et al30 |
| P16INK4A | |||
| LOH | 0 | 25 | Penzel et al25 |
| Loss of expression | 40-50 | 70 | Hirabyashi et al30 |
Abbreviations: FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; LOH, loss of heterozygosity.